Alnylam Pharmaceuticals, Inc.
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

Last updated:

Abstract:

The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.

Status:
Grant
Type:

Utility

Filling date:

1 May 2020

Issue date:

29 Mar 2022